Thus, HSP90-dependent cancer cells that have restored HSP90 function in the presence of PU-H71 via an HSP90α Y142N mutation or amplification and overexpression of ABCB1 may be targeted by alternative HSP90 inhibitors, such as ganetespib. The gene discussed is HSP90AB1; the disease is cancer.